Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

ZEISS Connected Quality: One metrology hub

The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Spatial Biology Studies in Lung Tissue using Spectral Microscopy

Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.

Petter Hartman: ”Existentiell egenvård i en kaotisk värld”

”Vår förmåga att möta livets svårigheter tycks hänga ihop med känslan av gemenskap och meningsfullhet”, skriver Petter Hartman i en krönika som tar upp regering...

Nytt läkemedel ska förenkla behandling av blödarsjuka

En ny typ av behandling mot hemofili, som bara behöver ges varannan månad, har godkänts av den amerikanska läkemedelsmyndigheten FDA.

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

Snabbtest ska säkra rätt hormonbehandling inför IVF

Forskare i Lund har tagit fram ett test som på en timme kan ge besked om vilken hormonbehandling som är mest lämplig inför en provrörsbefruktning, och som därme...

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

New Horizons in Biologics & Bioprocessing: Stockholm

Mastering Urine Microscopy

On-demand Webinar: Microscopy in urinalysis.

In search of Marcel Proust's lost health

A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...

Chalmersforskare: Bättre riskbedömning med lipoprotein än kolesterol

I stället för att mäta kolesterolvärdet i blodet för att förutse risken för hjärtinfarkt kan ett enkelt test av lipoproteinmarkörer ge bättre information. Det h...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

The Crucial Role of Core Imaging Facility Managers

User story from ZEISS and the University of York.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Han ska sprida Uppsalas gospel i världen

Hallå där... Magnus Lejelöv, ny verksamhetsledare för STUNS Life science.

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.